Fractyl Health (NASDAQ:GUTS) Releases Earnings Results, Misses Estimates By $0.08 EPS

Fractyl Health (NASDAQ:GUTS) issued its quarterly earnings data on Monday. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08), Zacks reports.

Fractyl Health Stock Performance

GUTS remained flat at $1.56 during midday trading on Monday. The company’s stock had a trading volume of 278,129 shares, compared to its average volume of 343,469. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The firm has a fifty day simple moving average of $1.78 and a two-hundred day simple moving average of $2.29. The stock has a market capitalization of $75.03 million and a PE ratio of -0.13. Fractyl Health has a 12-month low of $1.37 and a 12-month high of $10.50.

Insider Transactions at Fractyl Health

In related news, insider Jay David Caplan sold 22,346 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $1.81, for a total transaction of $40,446.26. Following the transaction, the insider now owns 153,544 shares of the company’s stock, valued at approximately $277,914.64. The trade was a 12.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Harith Rajagopalan sold 90,972 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $1.82, for a total transaction of $165,569.04. Following the completion of the sale, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at approximately $894,218.78. This trade represents a 15.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley cut their target price on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.